Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumours after kidney transplantation.

Jens Lutz1, Uwe Heemann

  • 1Department of Nephrology, II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Current Opinion in Urology
|February 14, 2003
PubMed
Summary

Malignancies are a significant cause of death in kidney transplant recipients. Strategies to manage cancer risk include careful immunosuppression selection and pre- and post-transplant screening.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiopulmonary resuscitation in donation after brain death donors aged ≥65 years: impact on outcomes after kidney transplantation - a multi-center study.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Impact of acute kidney injury in ≥65-year-old kidney donors on short- and long-term allograft outcomes.

Frontiers in medicine·2026
Same author

Endothelial dysfunction in Fabry disease: retinal biomarkers link cardiac GLA gene variants with chronic inflammation.

NPJ genomic medicine·2026
Same author

Long-term treatment patterns and outcomes in IgG4-related disease - a retrospective single-center cohort study focusing on rituximab.

Rheumatology international·2026
Same author

The Advanced Organ Support (ADVOS) hemodialysis system fulfills its intended purpose: Analysis of data from 282 patients from the Registry on Extracorporeal Multiple Organ Support (EMOS).

PloS one·2025
Same author

Continuous measurement of pulse arrival time for identification of blood pressure changes in patients undergoing hemodialysis-a feasibility study.

Clinical kidney journal·2025

Area of Science:

  • Nephrology
  • Oncology
  • Transplantation Immunology

Background:

  • Improved long-term survival in renal allograft recipients shifts focus to non-cardiovascular causes of morbidity and mortality.
  • Malignancies affect 15-20% of kidney transplant recipients within 10 years, significantly impacting outcomes.
  • Skin tumors and lymphoproliferative disorders are the most common cancers in this population, unlike the general population.

Purpose of the Study:

  • To review the incidence and contributing factors of malignancies in kidney transplant recipients.
  • To discuss the role of immunosuppression, viral infections, and donor transmission in cancer development.
  • To highlight the importance of screening and tailored immunosuppressive strategies.

Main Methods:

  • Review of current literature on malignancies in renal transplant recipients.

Related Experiment Videos

  • Analysis of the impact of different immunosuppressive strategies on cancer risk.
  • Evaluation of the role of chronic viral infections and donor-derived malignancies.

    • Main Results:

    • Cell-depleting antibodies increase malignancy risk, while agents like rapamycin may offer anti-tumor benefits.
    • The link between chronic viral infections and specific cancers (skin, lymphoproliferative) is increasingly understood.
    • The risk of malignancy transmission from donors, especially older ones, necessitates greater awareness.

    Conclusions:

    • Malignancies are a major cause of death in kidney transplant recipients, with incidence rising due to longer graft survival.
    • A combination of immunosuppression, chronic viral infections, donor transmission, and recurrent cancers drives the increased cancer incidence.
    • Mandatory pre- and post-transplant screening and individualized immunosuppression choices are crucial for managing cancer risk.